Project description DEENESFRITPL Novel platform for future treatment of multidrug-resistant microbial infections Many bacteria that cause infectious diseases develop resistance to available antibiotic drugs. Promising potential new drugs fail to progress to the clinic due to poor solubility, protein adsorption or difficulties in preparing pharmaceutical formulations. The EIC-funded LeadtoTreat project aims at addressing this problem by introducing a novel targeted delivery approach for compounds suitable for treating resistant microbial infections. Researchers plan to develop nano-formulations targeting pathogenic bacterial, as well as areas of inflammation, as a tool for simultaneous delivery of antibiotics and potentiators. Methicillin-resistant Staphylococcus aureus infections will be used to demonstrate the technology. This combinatorial treatment will contribute to a radical shift in the treatment approach of infections and is expected to help tackle the worldwide threat of antibiotics resistance. Show the project objective Hide the project objective Objective Many bacteria that cause infectious diseases develop resistance to not only the primary antibiotic treatments available in the clinic but also to drugs of last resort which often require long treatment periods and come with significant side effects. At the same time many promising lead compounds with high activity and wide therapeutic windows have failed to progress to clinical trials due to poor solubility, protein absorption or other difficulties in formulation (e.g. low drugability). LeadtoTreat proposes a new solution to these challenges by introduction of a platform for future infection treatment enabling targeted delivery of novel lead compounds with low drugability as well as synergistic combinations of antibiotics and potentiators in a nano-formulation. A novel dual targeting approach, with both direct targeting toward the pathogenic bacteria as well as to areas of inflammation will be employed. This platform technology will be demonstrated by converting a highly active, but insoluble and protein binding, novel compound into targeted nano-formulations for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections with proven in vivo and in vitro safety. Furthermore, LeadtoTreat aims to identify novel synergistic combinations of antibiotics and potentiators and convert these into highly active targeted nano-formulations for treatment of MRSA infections. LeadToTreat will have significant impact on the future treatment of microbial infections, by demonstrating a pathway to co-delivery of synergistic combination of existing antibiotics as well a path way to revitalize the huge library of abandoned low-drugability lead compounds. From an innovation perspective, it is expected to also develop broadly applicable targeting tools (for MRSA, and roadmap for other indications). The project will be managed by SINTEF (Norway) involving Narodowy Instytut Lekow (National Medicine Institute, NMI, Poland) and NanoTag Biotechnologies GmbH (NTB, Germany). Fields of science natural sciencesbiological sciencesmicrobiologybacteriologymedical and health scienceshealth sciencesinfectious diseasesnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics Keywords Nanotechnology Biotechnology Microbiology MRSA Formulation Programme(s) HORIZON.3.1 - The European Innovation Council (EIC) Main Programme HORIZON.3.1.1 - The Pathfinder for Advanced Research Topic(s) HORIZON-EIC-2021-PATHFINDEROPEN-01-01 - EIC Pathfinder Open 2021 Call for proposal HORIZON-EIC-2021-PATHFINDEROPEN-01 See other projects for this call Funding Scheme HORIZON-EIC - HORIZON EIC Grants Coordinator SINTEF AS Net EU contribution € 1 806 314,75 Address STRINDVEGEN 4 7034 Trondheim Norway See on map Region Norge Trøndelag Trøndelag Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 806 315,00 Participants (2) Sort alphabetically Sort by Net EU contribution Expand all Collapse all NARODOWY INSTYTUT LEKOW Poland Net EU contribution € 344 250,00 Address ULICA CHELMSKA 30/34 00 725 Warszawa See on map Region Makroregion województwo mazowieckie Warszawski stołeczny Miasto Warszawa Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 344 250,00 NANOTAG BIOTECHNOLOGIES GMBH Germany Net EU contribution € 515 000,00 Address RUDOLF WISSELL STRASSE 28A 37079 Gottingen See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Niedersachsen Braunschweig Göttingen Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 515 000,00
